Home Market The week in 10 stocks: Pharma, oil companies dance to the rupee’s...

The week in 10 stocks: Pharma, oil companies dance to the rupee’s tune


Turkeys financial issues and a falling rupee back home did create a scare for equities, but benchmarks Sensex and Nifty stood firm and ended the truncated week in the green. The NSE index, in fact, summoned courage to hit off a new record in the end.

For the whole week, the 30-share Sensex notched up 79 points, or 0.21 per cent, closing at 37,948. As for the Nifty, the record high came at 11,471, up 41.25 points, or 0.35 per cent, against a close of 11,430 on August 10.

Overall, fortunes seesawed the whole week. The beginning was on a downbeat note, with Fitch Ratings latest report that its outlook on the Indian banking sector is likely to remain negative until the banks address their weak core capital positions against mounting bad loans and poor financial performance.

In between, Indias trade deficit soared to a near five-year high of $18 billion. But it was the final day of trade that helped markets regain composure and settle the week in positive territory.

But there are top stocks and sectors that were up and running the whole week. A look.

@fresh all-time high: More than 25 stocks on the BSE 500 index scaled their fresh all-time high during the week gone by. Some of the stocks on the list included Varun Beverages, Jubilant FoodWorks, 3M India, Havells India, Berger Paints, Bajaj Finserv, Exide Industries, Bata India, Graphite India, Page Industries and Tata Consultancy Services.

Nifty top gainer: Sun Pharma played to the gallery, gaining the most, on the Nifty50 index. The scrip jumped 12.55 per cent to Rs 623.50 on August 17, from Rs 554 on August 10. The drug major got traction on better-than-expected results for the first quarter to June on the back of stronger sales in the US. It posted consolidated net profit of Rs 982.51 crore for Q1 FY19 against net loss of Rs 424.92 crore for Q1 FY18. In a separate development, the company received approval for CEQUA (cyclosporine ophthalmic solution) 0.09 per cent, from the USFDA. CEQUA is indicated for treatment of patients with keratoconjunctivitis sicca (dry eye).

Booster dose: Most pharma stocks advanced on the back of a weak rupee. The local currency plunged more than 9 per cent on a year-to-date (YTD) basis and around 2 per cent in August. A weak rupee boosts revenue of pharma firms in rupee terms as the sector derives a major share of revenue from exports. Besides Sun Pharma, Lupin, Dr Reddys Labs and Cipla advanced up to 8 per cent last week.

Rupee impact: Oil marketing companies (OMCs) came under pressure as the rupee went below 70 per dollar for the first time. Loss in the rupee against the dollar makes oil imports costlier for these companies. The sharp decline in the currency can be attributed to a weak external position with respect to current account deficit as well as an unstable political and currency environment in Turkey. HPCL, IOC and BPCL declined 4.09 per cent, 5.98 per cent and 6.50 per cent, respectively, during August 10-17.

Top gainers of BSE 500: With a rally of 47 per cent, Housing Development & Infrastructure stood out in the crowd. It was the top gainer on the BSE 500 index for the week ended August 17. It was followed by Apollo Hospitals (up 25 per cent), Kwality (21 per cent), United Breweries (15 per cent) and Rain Industries (13 per cent).

Top losers of BSE 500: Reliance Naval (down 17 per cent), Sobha (down 12 per cent), IL&FS Transportation Networks (down 11 per cent), Chennai Petroleum Corporation (down 10.76 per cent) and Allahabad Bank (down 10 per cent) ended up being top losers of the index during the week gone by.

Order boost: Shares of Ion Exchange (India) hit upper circuit of 5 per cent on Friday after the company signed up a job contract from a Vedanta unit. The company informed bourses that it has signed a contract for engineering, procurement, supply and construction of water treatment plant worth of Rs 438.84 crore from Cairn Oil & Gas, a division of Vedanta Ltd.

Apollo Hospitals: The stock spurted over 25 per cent after the healthcare company posted 71.02 per cent increase in its standalone PAT at Rs 60.2 crore for the first quarter ended June. Revenues grew by 16 per cent to Rs 1,910.4 crore for the first quarter from Rs 1,650.4 crore in the same period a year ago.

Original Article


Please enter your comment!
Please enter your name here